Neurocrine Biosciences, Inc. (LON:0K6R)
106.69
+2.04 (1.95%)
At close: Apr 25, 2025
Neurocrine Biosciences Revenue
In the year 2024, Neurocrine Biosciences had annual revenue of $2.36B USD with 24.81% growth. Neurocrine Biosciences had revenue of $627.70M in the quarter ending December 31, 2024, with 21.84% growth.
Revenue
$2.36B
Revenue Growth
+24.81%
P/S Ratio
4.22
Revenue / Employee
$1.31M
Employees
1,800
Market Cap
7.93B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.36B | 468.20M | 24.81% |
Dec 31, 2023 | 1.89B | 398.40M | 26.76% |
Dec 31, 2022 | 1.49B | 355.20M | 31.34% |
Dec 31, 2021 | 1.13B | 87.60M | 8.38% |
Dec 31, 2020 | 1.05B | 257.80M | 32.71% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Neurocrine Biosciences News
- 3 days ago - Neurocrine Biosciences publishes positive data from movement disorder study - Seeking Alpha
- 3 days ago - Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry - PRNewsWire
- 5 days ago - Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025 - Seeking Alpha
- 11 days ago - Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity - Seeking Alpha
- 12 days ago - This Triumph Group Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday - Benzinga
- 23 days ago - Neurocrine Biosciences names Sanjay Keswani as chief medical officer - Seeking Alpha
- 24 days ago - Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer - PRNewsWire
- 27 days ago - Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia - PRNewsWire